We found that over 50% of tumors in our screen had transposon insertions near MAPK pathway genes, suggesting that MAPK pathway inhibitors or HDAC inhibitors, like FK228, that significantly decrease RAF1 levels[68] may be effective therapeutics for HS patients. The gene discussed is RAF1; the disease is histiocytic sarcoma.